sur INVENTIVA (EPA:IVA)
Inventiva presents an abstract at the Liver Meeting™ 2024
Inventiva announces that its Phase II clinical trial, LEGEND, combining lanifibranor and empagliflozin, has been selected as a late breaker abstract for the Liver Meeting™ 2024, organized by the American Association for the Study of Liver Diseases. The event will be held in San Diego from November 15 to 19, 2024.
The LEGEND study is evaluating the combination of lanifibranor with empagliflozin in patients with metabolic steatohepatitis (MASH) and type 2 diabetes. It will be presented as a poster on November 18 by a team of experts, including Michelle Lai and Onno Holleboom.
Lanifibranor, developed by Inventiva, is known for its anti-fibrotic and anti-inflammatory effects in treating NASH. The company, listed on Euronext Paris and Nasdaq, continues to develop and test this treatment globally.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INVENTIVA